Hematopoiesis

Greyledge Technologies Receives $2.5 Million Convertible Loan from Publicly-Traded Lender to Expand Cell Processing Facilities and Data Management Capability

Retrieved on: 
Tuesday, March 30, 2021
Technology, Biotechnology, Health, Finance, Small business, Professional services, Other Science, Other Technology, Research, Managed care, General Health, Genetics, Science, Data management, Branches of biology, Anatomy, Stem cells, Organ systems, Bone marrow, Endocrine system, Hematopoiesis, Lymphatic system, Skeletal system, Greyledge

Greyledge is an industry-leading biotech and emerging growth company specializing in cell therapeutics produced from a patients own blood or bone marrow tissue.

Key Points: 
  • Greyledge is an industry-leading biotech and emerging growth company specializing in cell therapeutics produced from a patients own blood or bone marrow tissue.
  • The Company has refined its scientific technology, and since 2017, has been driven to achieve sustained profitability and scalability.
  • Greyledge currently operates in 4 states with 10 cell processing facilities.
  • Greyledge is headquartered in Denver, CO and operates services in 4 strategic states, Texas, Michigan, and Georgia, and currently operates 10 proprietary cell processing facilities.

Ossium Health Raises $63M Series B to Revolutionize Bioengineering

Retrieved on: 
Thursday, March 18, 2021
Branches of biology, Anatomy, Organ systems, Stem cells, Bone marrow, Endocrine system, Hematopoiesis, Lymphatic system, Skeletal system

Humanitys deepening understanding of biology is driving a revolution in bioengineering that parallels the industrial revolutions that followed the birth of modern physics and chemistry, said Ossium Co-Founder and CEO, Kevin Caldwell.

Key Points: 
  • Humanitys deepening understanding of biology is driving a revolution in bioengineering that parallels the industrial revolutions that followed the birth of modern physics and chemistry, said Ossium Co-Founder and CEO, Kevin Caldwell.
  • Ossiums $63M Series B is the latest financing for the five-year-old company which has raised a total of $74M.
  • What Ossium is building isn't just a new methodology for procuring the lifesaving therapeutics like bone marrow and stem cells.
  • The companys mission is to deploy cellular therapeutics and bioengineering to produce lasting gains in the health, vitality, and longevity of human beings.

NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia

Retrieved on: 
Tuesday, October 27, 2020
Branches of biology, Biology, Medical specialties, Stem cells, Biotechnology, Cell biology, Bone marrow, Hematopoiesis, Skeletal system, Leukemia, Hematopoietic stem cell transplantation, Organ transplantation

City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001.

Key Points: 
  • City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001.
  • City of Hope is a world-class clinical research institution that has built one of the largest banks of leukemia samples in the world, said Han Myint, M.D., NexImmune Chief Medical Officer.
  • More than 16,000 stem cell and bone marrow transplants have been performed at City of Hope, and more than 700 are performed annually.
  • NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology.

WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs®) Data Selected for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Retrieved on: 
Tuesday, October 20, 2020
Branches of biology, Biology, Stem cells, Medical specialties, Bone marrow, Endocrine system, Hematopoiesis, Lymphatic system, Skeletal system, Cancer immunotherapy, Cell therapy

Details of the presentation are as follows:

Key Points: 
  • Details of the presentation are as follows:
    A copy of the abstract can be viewed online through the SITC website .
  • The presentation will be available in the Virtual Poster Hall from November 9 14, 2020.
  • WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy.
  • As the leader in bone marrow-derived T cell therapies, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients.

WindMIL Therapeutics and Stephenson Cancer Center Announce Collaboration to Collect Bone Marrow from Patients with Renal and Urothelial Carcinomas to Develop Marrow Infiltrating Lymphocytes (MILs®)

Retrieved on: 
Tuesday, October 13, 2020
Branches of biology, Medical specialties, Lymphatic system, Stem cells, Hematopoiesis, Immune system, Lymph fluid, Lymphocyte, Bone marrow, Immunology, Cell therapy, Draft:Philip Greenberg, M.D.

The study will evaluate generating marrow infiltrating lymphocytes (MILs) for these patients through WindMILs proprietary cellular activation and expansion process.

Key Points: 
  • The study will evaluate generating marrow infiltrating lymphocytes (MILs) for these patients through WindMILs proprietary cellular activation and expansion process.
  • The bone marrow is a unique niche in the immune system to which antigen-experienced memory T cells traffic and are then maintained.
  • As the leader in bone marrow-derived T cell therapies, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients.
  • As Oklahomas only National Cancer Institute-Designated Cancer Center, Stephenson Cancer Center is one of the nations elite centers, representing the top 2% of cancer centers in the country.

New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function

Retrieved on: 
Thursday, October 8, 2020
Other Health, Public relations, Investor relations, Communications, General Health, Women, Seniors, Fitness & Nutrition, MEN, Science, Biotechnology, Alternative medicine, Consumer, Other Science, Health, Research, Branches of biology, Medical specialties, Biology, Immune system, Hematopoiesis, Histology, Immunology, Biotechnology, Haematopoiesis, Immunotherapy, T cell, Nicotinamide riboside

ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor infiltrating T-cells (TILs) in samples extracted from mice.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor infiltrating T-cells (TILs) in samples extracted from mice.
  • In a preclinical mouse model, NR was shown to improve T-cell function, which is a component of new cancer immunotherapies such as PD-1 and PDL-1 inhibitors.
  • This research built upon a previous preclinical study , also conducted at the University of Lausanne, that found NR could promote hemopoietic stem cell (HSC) maturation in mice by stimulating mitochondrial function.
  • We know mitochondrial function is essential to the function of energy-expensive cells, including stem cells and immune cells.

WindMIL Therapeutics to Present at Citi's 15th Annual BioPharma Virtual Conference

Retrieved on: 
Thursday, September 3, 2020
Medical specialties, Branches of biology, Lymphatic system, Stem cells, Hematopoiesis, Cancer immunotherapy, Bone marrow, Immunotherapy, Lymphocyte, Immunology, Draft:Philip Greenberg, M.D., Shimon Slavin

PHILADELPHIA and BALTIMORE, Sept. 03, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Citi's 15th Annual BioPharma Virtual Conference on Thursday, September 8, 2020 at 4:05 pm EDT.

Key Points: 
  • PHILADELPHIA and BALTIMORE, Sept. 03, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Citi's 15th Annual BioPharma Virtual Conference on Thursday, September 8, 2020 at 4:05 pm EDT.
  • WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy.
  • As the leader in bone marrow-derived T cell therapies, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients.
  • The companys proprietary process to activate, transform and expand T cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence.

WindMIL Therapeutics to Present at Jefferies Virtual Healthcare Conference 2020

Retrieved on: 
Wednesday, May 27, 2020
Medical specialties, Medicine, Lymphatic system, Stem cells, Hematopoiesis, Cancer treatments, Cancer immunotherapy, Bone marrow, Immunotherapy, Immunology, Lymphocyte, Shimon Slavin

PHILADELPHIA and BALTIMORE, May 27, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 8:00 am EDT.

Key Points: 
  • PHILADELPHIA and BALTIMORE, May 27, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 8:00 am EDT.
  • WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy.
  • As the leader in bone marrow-derived T cell therapies, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients.
  • The companys proprietary process to activate, transform and expand T cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence.

Q1-2020 Net Revenues increase 77% over Q4-2019 to $1.2M

Retrieved on: 
Friday, May 15, 2020
Animal anatomy, Organ systems, Branches of biology, Bone marrow, Endocrine system, Hematopoiesis, Skeletal system

Overall case volume increased 43% in Q1-2020 vs. Q4-2019 due to an 87% increase in Peripheral Blood (PB) samples and a 17% increase in Bone Marrow samples from both new and existing customers.

Key Points: 
  • Overall case volume increased 43% in Q1-2020 vs. Q4-2019 due to an 87% increase in Peripheral Blood (PB) samples and a 17% increase in Bone Marrow samples from both new and existing customers.
  • Recurring customers that ordered each month during the quarter increased 16% in Q1-2020 vs. Q4-2019 and increased 61% vs. Q1-2019.
  • Additionally, the increase of PB cases vs. the lower growth of BM cases as mentioned in Metric #2 impacted the ARPU.
  • This increase was driven by the improved performance from our newer sales representatives and the addition of the Oncometrix sales team.

WindMIL Therapeutics to Present at UBS Virtual Global Healthcare Conference

Retrieved on: 
Tuesday, May 12, 2020
Lymphatic system, Medical specialties, Medicine, Stem cells, Hematopoiesis, Cancer treatments, Cancer immunotherapy, Bone marrow, Immunotherapy, Immunology, Lymphocyte, Shimon Slavin

PHILADELPHIA and BALTIMORE, May 12, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 3:50 pm EDT.

Key Points: 
  • PHILADELPHIA and BALTIMORE, May 12, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy,today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 3:50 pm EDT.
  • WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy.
  • As the leader in bone marrow-derived T cell therapies, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients.
  • The companys proprietary process to activate, transform and expand T cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence.